Liquidia Corporation with ticker code (LQDA) have now 5 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 6 and 4 calculating the average target price we see 5.2. With the stocks previous close at 3.13 this would indicate that there is a potential upside of 66.1%. The 50 day moving average now sits at 3.32 and the 200 moving average now moves to 5.37. The market capitalisation for the company is $130m. Find out more information at: http://www.liquidia.com
Liquidia Corporation, through its subsidiaries, operates as a late-stage clinical biopharmaceutical company. The company focuses on the development and commercialization of various products using its PRINT technology that enables precise production of drug particles designed to enhance the safety, efficacy, and performance of a range of therapies. Its product candidates include LIQ861 for the treatment of pulmonary arterial hypertension; and LIQ865 for the treatment of local post-operative pain. The company also provides strategy, investment, and commercialization services for rare disease pharmaceutical products, such as generic Remodulin, a parenteral formulation of treprostinil for pulmonary arterial hypertension. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
